Nurse Practitioner in Hardeeville, SC Accepting Medicare
5 Nurse Practitioner nurses found. Showing 1 - 5
 Shawna Colleen Roberts, FNP-BC Nurse Practitioner - Family Medicare: Medicare Enrolled Practice Location: 1010 Medical Center Dr Ste 210, Hardeeville, SC 29927 Phone: 843-645-8220 Fax: 843-645-8221 |
Kellie Danielle Smith, FNP Nurse Practitioner - Primary Care Medicare: Not Enrolled in Medicare Practice Location: 120 Garden Row Dr S, Hardeeville, SC 29927 Phone: 843-929-2590 |
Nancy C Harris, FNP Nurse Practitioner - Family Medicare: Not Enrolled in Medicare Practice Location: 1010 Medical Center Dr, Suite D, Hardeeville, SC 29927 Phone: 843-784-8293 |
Mojirola Oguntoyinbo, NP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 552 Stiney Rd, Hardeeville, SC 29927 Phone: 843-784-2182 |
Kandralyn Steele, P.N.P. Nurse Practitioner - Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 300 New River Pkwy, Suite 16, Hardeeville, SC 29927 Phone: 843-203-5495 Fax: 843-782-3269 |
News Archive
Lung microbiome of critically ill patients is predictive of clinical outcomes
Changes in the lung microbiome may help predict how well critically ill patients will respond to care, according to new research published online in the American Thoracic Society's American Journal of Respiratory and Critical Care Medicine.
Derma Sciences fourth quarter total sales increase 12% to record $15.3 million
Derma Sciences, Inc., a medical device and pharmaceutical company focused on advanced wound care, today reported financial and operating results for the three and 12 months ended December 31, 2010.
Reprogramming liver cells to become pancreatic cells may help diabetic patients
It is now possible to reprogram cells from the liver into the precursor cells that give rise to the pancreas by altering the activity of a single gene.
Alnylam Pharmaceuticals earns $20M technology transfer payment from Takeda Pharmaceutical
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today announced that it has earned a $20 million technology transfer payment from Takeda Pharmaceutical Company Limited as part of the strategic alliance the companies formed in May 2008.
Stimatix reports interim results from artificial sphincter trial for restoring bowel control in people with stoma
Stimatix GI, located in the Misgav Venture Accelerator, has reported encouraging interim results in its animal trials of the AOS-C1000 artificial sphincter, designed to provide stoma patients with a new means of bowel control.
› Verified 1 days ago